The Central Drugs Standard Control Organisation (CDSCO) has been steadily tightening India's drug manufacturing quality standards through the revised Schedule M of the Drugs and Cosmetics Rules. For pharmaceutical manufacturers,…
The Central Drugs Standard Control Organisation (CDSCO) has signalled a major shift in India’s drug regulatory framework, moving toward a risk-based approach designed to reduce compliance burdens for pharmaceutical manufacturers…
Buying generic medicines in India can save significant money — but quality varies widely between manufacturers. According to the World Health Organization (WHO), generic medicines should be bioequivalent to their…
India's pharmaceutical regulatory landscape is undergoing significant transformation. In January 2026, the Government of India notified key amendments to the New Drugs & Clinical Trials (NDCT) Rules, introducing changes that…